Milestone Pharmaceuticals
MIST
29 hedge funds and large institutions have $116M invested in Milestone Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 2 closing their positions.
547% more call options, than puts
Call options by funds: $1.77M | Put options by funds: $273K
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
4% more funds holding
Funds holding: 28 → 29 (+1)
0.77% less ownership
Funds ownership: 70.35% → 69.58% (-0.77%)
14% less capital invested
Capital invested by funds: $135M → $116M (-$19.1M)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.07M |
| 2 |
LPC
Lion Point Capital
New York
|
+$1.63M |
| 3 |
BL
Bleichroeder LP
New York
|
+$1.61M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$474K |
| 5 |
Millennium Management
New York
|
+$427K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$4.71M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$3.38M |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$318K |
| 4 |
Barclays
London,
United Kingdom
|
-$92.2K |
| 5 |
PP
PDT Partners
New York
|
-$65K |
MIST Hedge Fund Activity: Q2 2022 in Review
29 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q2 2022, worth a combined $116M — down 14% from $135M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new MIST positions and 2 closed out — a net gain of 2 holders — while 6 added to existing stakes and 8 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $3.07M. The largest seller was OrbiMed, cutting an estimated $4.71M.
- 29 institutional investors held Milestone Pharmaceuticals (MIST) as of Q2 2022, up from 28 in Q1 2022.
- Funds reported $116M of Milestone Pharmaceuticals stock for Q2 2022, down 14% quarter-over-quarter.
- 4 funds opened new Milestone Pharmaceuticals positions in Q2 2022 and 2 closed out, a net change of +2 holders.
- The largest Milestone Pharmaceuticals buyer in Q2 2022 was Morgan Stanley, an estimated $3.07M added.
- The largest Milestone Pharmaceuticals seller in Q2 2022 was OrbiMed, an estimated $4.71M sold.
Based on aggregated 13F filings for Q2 2022.